Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Super Micro Computer Inc (SMCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Super Micro Computer Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Super Micro Computer Inc trades at $27.66 (market cap $18.31B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Super Micro Computer Inc's market cap. Which is the better fit depends on your goals.
| ALNY | SMCI | |
|---|---|---|
Market Cap | $39.89B | $18.31B |
Sector | Health | Technology |
52-Week High | $491.22 | $60.71 |
52-Week Low | $278.09 | $20.53 |
Enterprise Value | $38.15B | $25.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Super Micro Computer (SMCI) trades at $28.31, up 0.25% with bearish technical signals despite recent earnings beats. The stock faces headwinds from a Taiwan investigation into alleged AI server exports, contributing to a 36% decline in June. Fundamentally, the company shows strong revenue growth with $21.97B in 2025 and improved net income margins, but cash flow trends raise concerns with projected negative operating cash flow in 2026.
The investment outlook is mixed: valuation metrics appear attractive with P/E of 14.9 and P/S of 0.56, and analysts maintain a $36.43 price target. However, significant risks include the ongoing Taiwan probe, working capital pressures, and competitive threats in the AI infrastructure space that could impact future growth and margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →
